We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$27.2B
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter
Est. Return
+13.16%
1 Year Est. Return
+43.16%
3 Year Est. Return
+177.72%
5 Year Est. Return
+262.7%
10 Year Est. Return
+1,121.27%
AUM
$22.5B
AUM Growth
+$1.93B
(+9.4%)
Cap. Flow
+$256M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
26.61%
Holding
1,346
New
164
Increased
337
Reduced
605
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$426M |
| 2 |
Deere & Co
DE
|
+$212M |
| 3 |
NVIDIA
NVDA
|
+$149M |
| 4 |
W.W. Grainger
GWW
|
+$140M |
| 5 |
Netflix
NFLX
|
+$135M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$196M |
| 2 |
Home Depot
HD
|
+$189M |
| 3 |
Gilead Sciences
GILD
|
+$145M |
| 4 |
Oracle
ORCL
|
+$145M |
| 5 |
Microsoft
MSFT
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.24% |
| 2 | Financials | 13.5% |
| 3 | Healthcare | 12.02% |
| 4 | Consumer Discretionary | 11.94% |
| 5 | Industrials | 11.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Emergent Biosolutions
EBS
$230M
| $461K | ﹤0.01% |
+44,464
| New | +$537K |
|
877
Genworth Financial
GNW
$3.77B
| $460K | ﹤0.01% |
91,685
+1,931
| +2% | +$10.7K |
|
|
DBD
878
DELISTED
Diebold Nixdorf Incorporated
DBD
| $460K | ﹤0.01% |
383,422
+108,281
| +39% | +$241K |
|
879
Precigen
PGEN
$2.32B
| $459K | ﹤0.01% |
432,736
-13,162
| -3% | -$19K |
|
880
Chefs' Warehouse
CHEF
$4.57B
| $458K | ﹤0.01% |
13,455
-21,463
| -61% | -$754K |
|
|
OLO
881
DELISTED
Olo Inc
OLO
| $457K | ﹤0.01% |
+56,056
| New | +$431K |
|
882
CarGurus
CARG
$3.38B
| $456K | ﹤0.01% |
+24,405
| New | +$415K |
|
883
OFG Bancorp
OFG
$2.26B
| $455K | ﹤0.01% |
18,256
-1,423
| -7% | -$39.8K |
|
884
Insight Enterprises
NSIT
$4.6B
| $453K | ﹤0.01% |
3,169
-1,877
| -37% | -$234K |
|
885
Select Water Solutions
WTTR
$2.63B
| $453K | ﹤0.01% |
+65,025
| New | +$506K |
|
886
Sana Biotechnology
SANA
$1.1B
| $452K | ﹤0.01% |
138,338
-2,981
| -2% | -$11.9K |
|
|
MODN
887
DELISTED
MODEL N, INC.
MODN
| $452K | ﹤0.01% |
13,505
-1,129
| -8% | -$41.2K |
|
888
AMERISAFE
AMSF
$504M
| $452K | ﹤0.01% |
9,227
-1,000
| -10% | -$52.5K |
|
889
Rapid7
RPD
$929M
| $445K | ﹤0.01% |
+9,690
| New | +$412K |
|
890
Karyopharm Therapeutics
KPTI
$45.1M
| $442K | ﹤0.01% |
7,582
+788
| +12% | +$38.9K |
|
891
Aspen Aerogels
ASPN
$504M
| $442K | ﹤0.01% |
59,371
-42,784
| -42% | -$425K |
|
|
FBMS
892
DELISTED
The First Bancshares, Inc.
FBMS
| $436K | ﹤0.01% |
16,868
-12,280
| -42% | -$362K |
|
|
NUVA
893
DELISTED
NuVasive, Inc.
NUVA
| $435K | ﹤0.01% |
+10,539
| New | +$451K |
|
894
WSFS Financial
WSFS
$4.17B
| $432K | ﹤0.01% |
11,483
-7,620
| -40% | -$350K |
|
895
Laureate Education
LAUR
$5.15B
| $430K | ﹤0.01% |
+36,594
| New | +$403K |
|
|
LNW
896
DELISTED
Light & Wonder
LNW
| $430K | ﹤0.01% |
7,166
| – | – |
|
897
Jackson Financial
JXN
$9.1B
| $428K | ﹤0.01% |
11,441
+455
| +4% | +$18.7K |
|
898
Old Republic International
ORI
$10.3B
| $427K | ﹤0.01% |
17,086
+1,482
| +9% | +$37.3K |
|
899
ZipRecruiter
ZIP
$388M
| $427K | ﹤0.01% |
26,764
-10,762
| -29% | -$194K |
|
900
The Bancorp
TBBK
$2.82B
| $427K | ﹤0.01% |
15,317
+4,320
| +39% | +$137K |
|
Similar funds
FDCDDQ
WP
N
PCH
VAI
Los Angeles Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Los Angeles Capital Management held 1,346 positions worth $22.5B, up 9.4% from $20.6B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Los Angeles Capital Management's Q1 2023 filing shows 164 new, 337 increased, 605 reduced and 194 closed positions. Its largest new stake was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M. The largest sale was Pfizer, an estimated $196M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.
- Los Angeles Capital Management's largest Q1 2023 buy was Bio-Rad Laboratories Class A: 184,796 shares worth $88.5M.
- Los Angeles Capital Management added most to Visa in Q1 2023, an estimated $426M increase.
- Los Angeles Capital Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $196M.
- Los Angeles Capital Management fully exited Regions Financial in Q1 2023, selling an estimated $50.4M.
- Los Angeles Capital Management's ten largest holdings make up 27% of its $22.5B portfolio in Q1 2023.
- Los Angeles Capital Management opened 164 new positions and closed 194 in Q1 2023.
- Los Angeles Capital Management's portfolio value rose 9.4% quarter-over-quarter to $22.5B.
Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.